Active Biotech AB Interim report January - September 2014

Laquinimod
· Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting
· Teva initiated clinical studies with laquinimod in primary progressive MS (PPMS) and Huntington's disease
· The ongoing US pivotal clinical study CONCERTO is continuing according to plan. Results are expected in the first half of 2016

Tasquinimod     
· The Phase III study 10TASQ10 is proceeding according to the original schedule and results are expected in the first half of 2015

ANYARA
· Only out-licensing activities are being conducted
                    
Paquinimod (57-57)  
· Only out-licensing activities are being conducted

ISI
· CD selection expected in 2015.

New share issue
· Rights issue totaling approximately SEK 225 million to be approved by the Extraordinary General Meeting on December 1, 2014

Financial summary

MSEKJuly - Sept. January - Sept. Full Year 20142013 20142013 2013        Net sales2.6107.0 7.5111.9 116.0        Operating loss-55.727.9 -172.8-128.6 -209.0        Loss for the period-56.629.2 -174.5-130.0 -212.1        Loss per share (SEK)-0.760.39 -2.33-1.77 -2.87(before and after dilution)       

 

For further information, please contact:

Tomas Leanderson, President and CEO
 Tel: +46 (0)46 19 20 95
 
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.com

 

Active Biotech AB Interim report January - September 2014


This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
HUG#1868647